Evaluation of novel vanilloid-based hemostatic agents in rats

Himanshu Bhattacharjee, Steven N. Gurley, Patrick B. Allison, Xiofeng Zhang, Bob Moore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Hemostatic dressings containing clotting factors, biodegradable matrices, and recombinant proteins have been developed to control bleeding for battlefield trauma and trauma in clinical settings. Our present study evaluates the use of a vanilloid compound in biodegradable hemostatic dressings in a rat model of trauma. METHODS: Male Sprague-Dawley rats (n = 180) were randomly divided into treatment groups and control groups and subjected to a lethal groin injury at 30°C and 37°C. Treatment groups included hemostatic matrices consisting of Protosan and graded doses of 2.5%, 5%, 10%, 15%, and 20% of the vanilloid agonist CAP-305. Powder or bilayer patch formulations were applied to the injury site. The seal integrity was assessed by reperfusion of the animal to a minimum mean-arterial pressure (MAP) of 80 mm Hg and monitoring for 60 minutes postinjury. RESULTS: Powder and patch formulations loaded with varying concentrations of CAP-305 were evaluated. Powders containing 2.5% to 20% drug by weight showed 40% to 80% seal rates at 37°C (p < 0.0001), whereas no significant results were obtained at 30°C compared with the control animals. Conversely, bilayer patches loaded with 5% to 20% drug exhibited a consistent 70% seal rate (p < 0.0001) at 37°C and 70% to 90% seal rates (p < 0.0001) in hypothermic animals when compared with controls. CONCLUSIONS: Our study demonstrates the efficacy of CAP-305 loaded hemostatic dressings in the rat model of lethal groin injury. This study provides relevant proof of concept for the development of vanilloid agonists as hemostatic agents.

Original languageEnglish (US)
Pages (from-to)676-680
Number of pages5
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume68
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Hemostatics
Wounds and Injuries
Bandages
Powders
Groin
Blood Coagulation Factors
Recombinant Proteins
Pharmaceutical Preparations
Reperfusion
Sprague Dawley Rats
Arterial Pressure
Hemorrhage
Weights and Measures
Control Groups

All Science Journal Classification (ASJC) codes

  • Surgery
  • Critical Care and Intensive Care Medicine

Cite this

Evaluation of novel vanilloid-based hemostatic agents in rats. / Bhattacharjee, Himanshu; Gurley, Steven N.; Allison, Patrick B.; Zhang, Xiofeng; Moore, Bob.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 68, No. 3, 01.03.2010, p. 676-680.

Research output: Contribution to journalArticle

Bhattacharjee, Himanshu ; Gurley, Steven N. ; Allison, Patrick B. ; Zhang, Xiofeng ; Moore, Bob. / Evaluation of novel vanilloid-based hemostatic agents in rats. In: Journal of Trauma - Injury, Infection and Critical Care. 2010 ; Vol. 68, No. 3. pp. 676-680.
@article{2232c50032864c0a862a4229a635ca46,
title = "Evaluation of novel vanilloid-based hemostatic agents in rats",
abstract = "BACKGROUND: Hemostatic dressings containing clotting factors, biodegradable matrices, and recombinant proteins have been developed to control bleeding for battlefield trauma and trauma in clinical settings. Our present study evaluates the use of a vanilloid compound in biodegradable hemostatic dressings in a rat model of trauma. METHODS: Male Sprague-Dawley rats (n = 180) were randomly divided into treatment groups and control groups and subjected to a lethal groin injury at 30°C and 37°C. Treatment groups included hemostatic matrices consisting of Protosan and graded doses of 2.5{\%}, 5{\%}, 10{\%}, 15{\%}, and 20{\%} of the vanilloid agonist CAP-305. Powder or bilayer patch formulations were applied to the injury site. The seal integrity was assessed by reperfusion of the animal to a minimum mean-arterial pressure (MAP) of 80 mm Hg and monitoring for 60 minutes postinjury. RESULTS: Powder and patch formulations loaded with varying concentrations of CAP-305 were evaluated. Powders containing 2.5{\%} to 20{\%} drug by weight showed 40{\%} to 80{\%} seal rates at 37°C (p < 0.0001), whereas no significant results were obtained at 30°C compared with the control animals. Conversely, bilayer patches loaded with 5{\%} to 20{\%} drug exhibited a consistent 70{\%} seal rate (p < 0.0001) at 37°C and 70{\%} to 90{\%} seal rates (p < 0.0001) in hypothermic animals when compared with controls. CONCLUSIONS: Our study demonstrates the efficacy of CAP-305 loaded hemostatic dressings in the rat model of lethal groin injury. This study provides relevant proof of concept for the development of vanilloid agonists as hemostatic agents.",
author = "Himanshu Bhattacharjee and Gurley, {Steven N.} and Allison, {Patrick B.} and Xiofeng Zhang and Bob Moore",
year = "2010",
month = "3",
day = "1",
doi = "10.1097/TA.0b013e3181b0d616",
language = "English (US)",
volume = "68",
pages = "676--680",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Evaluation of novel vanilloid-based hemostatic agents in rats

AU - Bhattacharjee, Himanshu

AU - Gurley, Steven N.

AU - Allison, Patrick B.

AU - Zhang, Xiofeng

AU - Moore, Bob

PY - 2010/3/1

Y1 - 2010/3/1

N2 - BACKGROUND: Hemostatic dressings containing clotting factors, biodegradable matrices, and recombinant proteins have been developed to control bleeding for battlefield trauma and trauma in clinical settings. Our present study evaluates the use of a vanilloid compound in biodegradable hemostatic dressings in a rat model of trauma. METHODS: Male Sprague-Dawley rats (n = 180) were randomly divided into treatment groups and control groups and subjected to a lethal groin injury at 30°C and 37°C. Treatment groups included hemostatic matrices consisting of Protosan and graded doses of 2.5%, 5%, 10%, 15%, and 20% of the vanilloid agonist CAP-305. Powder or bilayer patch formulations were applied to the injury site. The seal integrity was assessed by reperfusion of the animal to a minimum mean-arterial pressure (MAP) of 80 mm Hg and monitoring for 60 minutes postinjury. RESULTS: Powder and patch formulations loaded with varying concentrations of CAP-305 were evaluated. Powders containing 2.5% to 20% drug by weight showed 40% to 80% seal rates at 37°C (p < 0.0001), whereas no significant results were obtained at 30°C compared with the control animals. Conversely, bilayer patches loaded with 5% to 20% drug exhibited a consistent 70% seal rate (p < 0.0001) at 37°C and 70% to 90% seal rates (p < 0.0001) in hypothermic animals when compared with controls. CONCLUSIONS: Our study demonstrates the efficacy of CAP-305 loaded hemostatic dressings in the rat model of lethal groin injury. This study provides relevant proof of concept for the development of vanilloid agonists as hemostatic agents.

AB - BACKGROUND: Hemostatic dressings containing clotting factors, biodegradable matrices, and recombinant proteins have been developed to control bleeding for battlefield trauma and trauma in clinical settings. Our present study evaluates the use of a vanilloid compound in biodegradable hemostatic dressings in a rat model of trauma. METHODS: Male Sprague-Dawley rats (n = 180) were randomly divided into treatment groups and control groups and subjected to a lethal groin injury at 30°C and 37°C. Treatment groups included hemostatic matrices consisting of Protosan and graded doses of 2.5%, 5%, 10%, 15%, and 20% of the vanilloid agonist CAP-305. Powder or bilayer patch formulations were applied to the injury site. The seal integrity was assessed by reperfusion of the animal to a minimum mean-arterial pressure (MAP) of 80 mm Hg and monitoring for 60 minutes postinjury. RESULTS: Powder and patch formulations loaded with varying concentrations of CAP-305 were evaluated. Powders containing 2.5% to 20% drug by weight showed 40% to 80% seal rates at 37°C (p < 0.0001), whereas no significant results were obtained at 30°C compared with the control animals. Conversely, bilayer patches loaded with 5% to 20% drug exhibited a consistent 70% seal rate (p < 0.0001) at 37°C and 70% to 90% seal rates (p < 0.0001) in hypothermic animals when compared with controls. CONCLUSIONS: Our study demonstrates the efficacy of CAP-305 loaded hemostatic dressings in the rat model of lethal groin injury. This study provides relevant proof of concept for the development of vanilloid agonists as hemostatic agents.

UR - http://www.scopus.com/inward/record.url?scp=77949481954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949481954&partnerID=8YFLogxK

U2 - 10.1097/TA.0b013e3181b0d616

DO - 10.1097/TA.0b013e3181b0d616

M3 - Article

VL - 68

SP - 676

EP - 680

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 3

ER -